Skip to main content
Premium Trial:

Request an Annual Quote

Skin Cancer Dx Firm Speclipse Raises Nearly $8M to Expand Business

NEW YORK – Korean diagnostics company Speclipse announced on Thursday that it has raised $7.7 million to develop additional applications for its technology.

Signite Partners, BNH Investment, Shinhan Capital, and MiCo were the main contributors to the financing. MiCoBioMed, a MiCo affiliate, also contributed.

The firm's laser spectroscopic technique and artificial intelligence technology were originally used for skin cancer diagnosis from tissue, and Speclipse said it plans to apply its tech to blood analysis.

The laser spectroscopic technology "overcomes the limitations of existing blood analysis technologies" because it can detect small variances in various blood biomarkers, the Seoul, South Korea-based company said in a statement. It also uses AI and deep learning to process and analyze large amounts of blood spectroscopic data, enabling early diagnosis of gastric cancer and Alzheimer's disease, it added.

Speclipse previously launched the Spectra-Scope, a skin cancer diagnosis device that uses laser-induced plasma spectroscopy. The instrument received CE marking in Europe and medical device certification in Australia and Brazil last year.